3 results about "Radioresistance" patented technology

In the present invention, the mRNA of the genes VTN, CXCL5, NEDD4, LCN2, SYTL4, TNFR2, and SERPING1, or the proteins encoded by these genes, exhibit differential expression levels in radioresistant lung cancer cells compared to control lung cancer cells and have a close correlation with a decrease in the survival rate of lung cancer patients. Accordingly, this preparation for measuring the expression levels of the mRNA of the genes selected from the group consisting of VTN, CXCL5, NEDD4, LCN2, SYTL4, TNFR2, and SERPING1 of the present invention or the expression levels of the proteins encoded by the genes can effectively diagnose radiation resistance in lung cancer or prognose radiation therapy for lung cancer, whereby it is possible to determine whether to perform radiation therapy and the optimal dose of radiation therapy, thus improving the efficiency and therapeutic outcomes of radiation therapy for lung cancer.

This invention relates to the application of DTX3 or reagents that promote DTX3 expression in the preparation of products reversing radioresistance in nasopharyngeal carcinoma (NPC), belonging to the field of biomedical technology. The invention found that, compared to parental NPC cells, Deltex E3 ubiquitin ligase 3 (DTX3) expression is significantly reduced in radioresistant NPC. Overexpression of DTX3 can reverse radioresistance in NPC cells and inhibit homologous recombination repair after radiotherapy in NPC, thus allowing DTX3 to be used to reverse radioresistance in NPC. This invention provides a new biomarker for the diagnosis of radiotherapy response in NPC, an effective method for reversing radioresistance in NPC, and a new treatment option for NPC.